Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

485 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia-a phase 3 study.
Braess J, Amler S, Kreuzer KA, Spiekermann K, Lindemann HW, Lengfelder E, Graeven U, Staib P, Ludwig WD, Biersack H, Ko YD, Uppenkamp MJ, De Wit M, Korsten S, Peceny R, Gaska T, Schiel X, Behringer DM, Kiehl MG, Zinngrebe B, Meckenstock G, Roemer E, Medgenberg D, Spaeth-Schwalbe E, Massenkeil G, Hindahl H, Schwerdtfeger R, Trenn G, Sauerland C, Koch R, Lablans M, Faldum A, Görlich D, Bohlander SK, Schneider S, Dufour A, Buske C, Fiegl M, Subklewe M, Braess B, Unterhalt M, Baumgartner A, Wörmann B, Beelen D, Hiddemann W; AML-CG. Braess J, et al. Among authors: biersack h. Leukemia. 2018 Dec;32(12):2558-2571. doi: 10.1038/s41375-018-0268-9. Epub 2018 Oct 1. Leukemia. 2018. PMID: 30275528 Free PMC article. Clinical Trial.
A retrospective comparison of autologous and unrelated donor hematopoietic cell transplantation in myelodysplastic syndrome and secondary acute myeloid leukemia: a report on behalf of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).
Al-Ali HK, Brand R, van Biezen A, Finke J, Boogaerts M, Fauser AA, Egeler M, Cahn JY, Arnold R, Biersack H, Niederwieser D, de Witte T. Al-Ali HK, et al. Among authors: biersack h. Leukemia. 2007 Sep;21(9):1945-51. doi: 10.1038/sj.leu.2404774. Epub 2007 Jul 5. Leukemia. 2007. PMID: 17611571
Lenalidomide, adriamycin, dexamethasone for induction followed by stem-cell transplant in newly diagnosed myeloma.
Knop S, Langer C, Engelhardt M, Mügge LO, Reichle A, Rösler W, Bassermann F, Hertenstein B, Kunitz A, Röllig C, Ostermann H, Schäfer-Eckart K, Ringhoffer M, Günther A, Junghanss C, Biersack H, Schreder M, Liebert A, Held S, Einsele H, Bargou RC. Knop S, et al. Among authors: biersack h. Leukemia. 2017 Aug;31(8):1816-1819. doi: 10.1038/leu.2017.124. Epub 2017 Apr 25. Leukemia. 2017. PMID: 28439106 Clinical Trial. No abstract available.
Favorable prognostic impact of RAS mutation status in multiple myeloma treated with high-dose melphalan and autologous stem cell support in the era of novel agents: a single center perspective.
Gebauer N, Biersack H, Czerwinska AC, Schemme J, Hardel TT, Bernard V, Rades D, Lehnert H, Luley KB, Thorns C. Gebauer N, et al. Among authors: biersack h. Leuk Lymphoma. 2016;57(1):226-9. doi: 10.3109/10428194.2015.1046863. Epub 2015 Jun 18. Leuk Lymphoma. 2016. PMID: 25947035 No abstract available.
Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial.
de Witte T, Hagemeijer A, Suciu S, Belhabri A, Delforge M, Kobbe G, Selleslag D, Schouten HC, Ferrant A, Biersack H, Amadori S, Muus P, Jansen JH, Hellström-Lindberg E, Kovacsovics T, Wijermans P, Ossenkoppele G, Gratwohl A, Marie JP, Willemze R. de Witte T, et al. Among authors: biersack h. Haematologica. 2010 Oct;95(10):1754-61. doi: 10.3324/haematol.2009.019182. Epub 2010 May 21. Haematologica. 2010. PMID: 20494931 Free PMC article. Clinical Trial.
Single nucleotide polymorphisms in TP53 but not KRAS or MDM2 are predictive of clinical outcome in multiple myeloma treated with high-dose melphalan and autologous stem cell support.
Gebauer N, Biersack H, Czerwinska AC, Schemme J, Hardel TT, Bernard V, Rades D, Lehnert H, Luley KB, Thorns C. Gebauer N, et al. Among authors: biersack h. Leuk Lymphoma. 2016;57(6):1482-6. doi: 10.3109/10428194.2015.1099648. Epub 2015 Nov 16. Leuk Lymphoma. 2016. PMID: 26414189 No abstract available.
485 results